Atea Pharmaceuticals has been granted a patent for a method of treating RNA virus infections in humans, including yellow fever, West Nile, Zika, and Japanese B encephalitis, using a specific compound. GlobalData’s report on Atea Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Atea Pharmaceuticals, Recombinant AAV gene therapy was a key innovation area identified from patents. Atea Pharmaceuticals's grant share as of May 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11975016B2) discloses a method for treating humans infected with viruses such as yellow fever, West Nile, Zika, and Japanese B encephalitis. The method involves administering a compound Formula IIIe, with specific variations in its chemical structure outlined in the claims. The compound is administered in various dosage forms suitable for oral, intravenous, or parental administration, including solid forms like tablets or capsules.
The claims specify different scenarios where the compound Formula IIIe is effective against specific viruses like yellow fever, West Nile, Zika, and Japanese B encephalitis. The method allows for flexibility in the dosage form, ensuring ease of administration to patients in need. This patent provides a structured approach to treating viral infections, offering potential solutions for individuals affected by these diseases. The compound's efficacy against a range of viruses highlights its versatility and potential impact in the field of antiviral treatments.
To know more about GlobalData’s detailed insights on Atea Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
